Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's drug candidates and their regulatory prospects [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to contact them for discussing legal options [1]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false and misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [5]. - The allegations suggest that the overstated claims about these drugs' prospects could significantly negatively impact Biohaven's business and financial condition once revealed [5]. Group 3: Stock Price Impact - Following a press release on May 14, 2025, regarding the extension of the PDUFA date for the troriluzole NDA, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [6].

NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submissio ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Biohaven securities is from March 24, 2023, to May 14, 2025, and the lead plaintiff deadline is September 12, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3] Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that the overstated claims about the drug's prospects likely had a significant negative impact on Biohaven's business and financial condition [4] - The lawsuit asserts that once the true details were revealed, investors suffered damages due to the misleading public statements [4]

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=157781&from=3 CLASS PERIOD: March 24, 2023 to Ma ...

LOS ANGELES, July 24, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR BIOHAVEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOV ...

NEW YORK, July 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=157774&from=4CLASS PERIOD: March 24, 2023 to May 14, 20 ...

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=157193&from=3 CLASS PERIOD: March 24, 2023 to Ma ...

NEW YORK, July 21, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 12, 2025.So What: If you purchased Biohaven securities during the Class Period you may ...

NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to dis ...